Street Crowns Sarepta DMD Gene Therapy King After Pfizer Results

(Bloomberg) -- Wall Street analysts are more bullish on Sarepta Therapeutics Inc. and its market-leading gene therapy for Duchenne muscular dystrophy after Pfizer Inc.’s early results for a competi...

Bloomberg Quint

Add BloombergQuint App to Home screen.